

John E Harrison

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2502602/john-e-harrison-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72
papers

2,537
citations

24
h-index

49
g-index

100
ext. papers

3,069
ext. citations

4.9
avg, IF

5.46
L-index

#	Paper	IF	Citations
72	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008 , 7, 779-86	24.1	577
71	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 509-16	4.3	306
70	Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. <i>Journal of Alzheimer's Disease</i> , 2012 , 31, 225-36	4.3	202
69	A neuropsychological test battery for use in Alzheimer disease clinical trials. <i>Archives of Neurology</i> , 2007 , 64, 1323-9		151
68	Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. <i>Alzheimer's and Dementia</i> , 2017 , 13, 468-492	1.2	84
67	Cognitive Impairment Associated with Cancer: A Brief Review. <i>Innovations in Clinical Neuroscience</i> , 2018 , 15, 36-44	1	81
66	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 21	9	69
65	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 873-881	4.6	63
64	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. <i>Alzheimer's and Dementia</i> , 2017 , 13, 186-195	1.2	61
63	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). <i>Trials</i> , 2019 , 20, 191	2.8	57
62	Safety, tolerability and efficacy of the glutamyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 107	9	48
61	Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 120-7	3.1	47
60	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. <i>European Heart Journal</i> , 2018 , 39, 374-381	9.5	44
59	Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 471-80	4.3	40
58	Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 8	9	39
57	Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study. <i>Journal of Affective Disorders</i> , 2015 , 171, 85-92	6.6	38
56	Which Cognitive Domains are Improved by Treatment with Vortioxetine?. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	37

55	FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 13-19	6	35
54	A randomized placebo controlled trial of vitamin B supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B. <i>Clinical Nutrition</i> , 2017 , 36, 1509-1515	5.9	33
53	Exploring the contribution of spatial navigation to cognitive functioning in older adults. <i>Neurobiology of Aging</i> , 2017 , 51, 67-70	5.6	31
52	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1131-1139	4.3	27
51	Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1991-8	1.2	25
50	A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. <i>Clinical Nutrition</i> , 2020 , 39, 2399-2405	5.9	24
49	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 130-138	6	22
48	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 222, 14-20	6.6	20
47	Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations. <i>Digital Biomarkers</i> , 2020 , 4, 99-108	7.1	19
46	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021 , 1, 521-534		17
45	Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans. <i>Psychopharmacology</i> , 2017 , 234, 535-547	4.7	15
44	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018 , 27, e1736	4.3	14
43	Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists. <i>Journal of Affective Disorders</i> , 2017 , 207, 346-352	6.6	14
42	Measuring the mind: assessing cognitive change in clinical drug trials. <i>Expert Review of Clinical Pharmacology</i> , 2008 , 1, 471-3	3.8	14
41	The evaluation of cognitive function in the dementias: methodological and regulatory considerations. <i>Dialogues in Clinical Neuroscience</i> , 2003 , 5, 77-88	5.7	14
40	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 47	9	14
39	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , 2016 , 3, 499	23.3	13
38	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2014 , 3, 158-69	2.5	13

37	Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB. <i>Clinical Neuropsychologist</i> , 2014 , 28, 252-68	4.4	12
36	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 45	9	11
35	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 153-160	5.2	9
34	Cognitive approaches to early Alzheimer's disease diagnosis. <i>Medical Clinics of North America</i> , 2013 , 97, 425-38	7	9
33	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 154-162	1.8	9
32	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017 , 15, 62-67	1.9	8
31	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 106	9	8
30	The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12020	6	8
29	Charles Darwin's emotional expression "experiment" and his contribution to modern neuropharmacology. <i>Journal of the History of the Neurosciences</i> , 2010 , 19, 158-70	0.7	7
28	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018 , 238, 228-232	6.6	6
27	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.. <i>Journal of Psychopharmacology</i> , 2022 , 36, 114-125	4.6	6
26	Cognitive Deficits in Brain Disorders		6
25	Evaluating cognitive dysfunction in major depressive disorder		6
24	Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study. <i>Journal of Prevention of Alzheimer's Disease</i> , 2018 , 5, 236-244	3.8	5
23	Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 1203-1210	4.3	4
22	The Assessment of Cognition in Translational Medicine: A Contrast Between the Approaches Used in Alzheimer's Disease and Major Depressive Disorder. <i>Handbook of Behavioral Neuroscience</i> , 2019 , 29, 297-308	0.7	4
21	Screening and measurement of cognitive impairment in psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 144-153	1.8	3
20	Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2016 , 46, 1455-63	4.6	3

19	Evaluation of the effect of Cooled HaEmodialysis on Cognitive function in patients suffering with end-stage KidnEy Disease (E-CHECKED): feasibility randomised control trial protocol. <i>Trials</i> , 2020 , 21, 820	2.8	3
18	Routine cognitive testing for all drugs?. <i>Drug Discovery Today</i> , 2002 , 7, 101-2	8.8	2
17	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach.. <i>Journal of Alzheimer's Disease</i> , 2022 ,	4.3	2
16	[P3015]: THE IMPACT OF ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECO) ON ALZHEIMER'S DISEASE CLINICAL TRIAL DATA QUALITY 2017 , 13, P935		1
15	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. <i>Drug Discovery Today</i> , 2021 , 26, 1330-1336	8.8	1
14	[P4078]: EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BAC-APP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY 2017 , 13, P1574-P1575		0
13	Asynchronous Remote Assessment for Cognitive Impairment: Reliability Verification of the Neurotrack Cognitive Battery.. <i>JMIR Formative Research</i> , 2022 , 6, e34237	2.5	0
12	Behavioural symptoms in Alzheimer's disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045223	1.2	2
11	Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045899	1.2	
10	Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046004	1.2	
9	Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046068	1.2	
8	[P4008]: QUALITY ASPECTS OF A NOVEL COGNITIVE-FUNCTIONAL COMPOSITE FOR THE MEASUREMENT OF DISEASE PROGRESSION IN ALZHEIMER'S DISEASE: FEASIBILITY, TEST-RETEST RELIABILITY AND PRACTICE EFFECTS 2017 , 13, P1256-P1257		
7	P4-123: Scopolamine disrupts allocentric spatial navigation in humans: The study in a real-space analogue of the morris water maze 2015 , 11, P825-P825		
6	Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12009	5.2	
5	P2-300: Capturing Changes in Cognition: The Needs and Wishes of Dementia Researchers and Clinicians 2016 , 12, P748-P748		
4	P4-113: COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT 2018 , 14, P1482-P1482		
3	P3-225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON-DIABETIC ALZHEIMER'S PATIENTS 2018 , 14, P1157-P1158		
2	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol.. <i>BMJ Open</i> , 2022 , 12, e052250	3	

1 The Use and Development of Clinical Measures of Alzheimer's Disease Trials **2022**, 281-291